First U.S. Clinical Site Opens for Cel-Sci's Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion
CEL-SCI Corporation announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries.
View full press release